Alzheimers Disease Diagnostic Market Size, Share, and Analysis, By Type (Early Onset Alzheimers, Late Onset Alzheimers, Familial Alzheimers Disease, Others), By Diagnostic Test (PET, SPECT, Blood based ELISA Test, CSF Assays, Others), By End User (Clinic, Hospital, Diagnostic Center, Others) and Regional Forecasts, 2022-2032
Alzheimers Disease Diagnostic Market Size, Share, and Analysis, By Type (Early Onset Alzheimers, Late Onset Alzheimers, Familial Alzheimers Disease, Others), By Diagnostic Test (PET, SPECT, Blood based ELISA Test, CSF Assays, Others), By End User (Clinic, Hospital, Diagnostic Center, Others) and Regional Forecasts, 2022-2032
PRODUCT OVERVIEW
Alzheimers Disease Diagnostic Market size was USD 3.3 billion in 2021 and projected t%li%grow from USD 4.0 billion in 2023 t%li%USD 9.6 billion by 2032, exhibiting a CAGR of 10.2% during the forecast period.
Alzheimer's is a brain illness that gradually impairs thinking and memory abilities as well as the capacity t%li%d%li%even the most basic tasks. Growing age is the key known risk aspect for the said disease. Alzheimer's is diagnosed by doctors using a patient's mental status tests, medical history, neurological and physical examinations, diagnostic tests, and brain imaging. The illness is the most typical cause of dementia in elderly people.
MARKET HIGHLIGHTS
Alzheimers Disease Diagnostic Market is expected t%li%reach USD 9.6 billion, growing at a CAGR of 10.2% during the forecast period owing t%li%increasing number of chronic illnesses like dementia, rising pipeline medicine development, and funding in biomarkers for development of drugs. The expanding treatment choices and better diagnostic procedures for the early finding of chronic illnesses is another major driver for the growth of the Alzheimers Disease Diagnostic Market.
Alzheimers Disease Diagnostic Market Segments:
Growth Drivers
Global Rise in Chronic Illnesses and Improvements in Diagnostics and Detection of Alzheimers is Expected t%li%Boost the Market Growth
Number of Government Initiatives and Funding by Institutions for R&D are Expected t%li%Boost the Market Growth
Restraint
Lengthy Clinical Trials and Huge Investments with Risk of Failure May Restrain the Market Growth
Key Players
PRODUCT OVERVIEW
Alzheimers Disease Diagnostic Market size was USD 3.3 billion in 2021 and projected t%li%grow from USD 4.0 billion in 2023 t%li%USD 9.6 billion by 2032, exhibiting a CAGR of 10.2% during the forecast period.
Alzheimer's is a brain illness that gradually impairs thinking and memory abilities as well as the capacity t%li%d%li%even the most basic tasks. Growing age is the key known risk aspect for the said disease. Alzheimer's is diagnosed by doctors using a patient's mental status tests, medical history, neurological and physical examinations, diagnostic tests, and brain imaging. The illness is the most typical cause of dementia in elderly people.
MARKET HIGHLIGHTS
Alzheimers Disease Diagnostic Market is expected t%li%reach USD 9.6 billion, growing at a CAGR of 10.2% during the forecast period owing t%li%increasing number of chronic illnesses like dementia, rising pipeline medicine development, and funding in biomarkers for development of drugs. The expanding treatment choices and better diagnostic procedures for the early finding of chronic illnesses is another major driver for the growth of the Alzheimers Disease Diagnostic Market.
Alzheimers Disease Diagnostic Market Segments:
- Type
- Early Onset Alzheimers
- Late Onset Alzheimers
- Familial Alzheimers Disease
- Others
- Diagnostic Test
- PET
- SPECT
- Blood based ELISA Test
- CSF Assays
- Others
- End User
- Clinic
- Hospital
- Diagnostic Center
- Others
Growth Drivers
Global Rise in Chronic Illnesses and Improvements in Diagnostics and Detection of Alzheimers is Expected t%li%Boost the Market Growth
Number of Government Initiatives and Funding by Institutions for R&D are Expected t%li%Boost the Market Growth
Restraint
Lengthy Clinical Trials and Huge Investments with Risk of Failure May Restrain the Market Growth
Key Players
- Johnson & Johnson
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Merck & Co.
- GE Healthcare
- AbbVie
- Eli Lilly and Company
- Daiichi Sankyo
- Sysmex
- Quanterix
- Alector LLC
- Corium Inc
- TauRx Therapeutics
- Cognition Therapeutics Inc
- Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)
- North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
- Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
- Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
- Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
- Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected t%li%witness the fastest growth as well as t%li%dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect t%li%recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight int%li%the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years t%li%come
- 3-month post-sales analyst support.
1. EXECUTIVE SUMMARY
1.1.Regional Market Share
1.2. Business Trends
1.3. Alzheimers Disease Diagnostic Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot
2. RESEARCH METHODOLOGY
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6.Market Size Estimation and Data Triangulation
3. MARKET CHARACTERISTICS
3.1. Market Definition
3.2.Alzheimers Disease Diagnostic Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. ALZHEIMERS DISEASE DIAGNOSTIC MARKET – INDUSTRY INSIGHTS
4.1.Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5. MACROECONOMIC INDICATORS
6. RECENT DEVELOPMENTS
7.MARKET DYNAMICS
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends
8. MARKET ANALYSIS
8.1. Porters Five Forces
8.2. PEST Analysis
8.2.1. Political
8.2.2.Economic
8.2.3.Social
8.2.4.Technological
9. ALZHEIMERS DISEASE DIAGNOSTIC MARKET
9.1. Overview
9.2.Historical Analysis (2016-2021)
9.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
10. ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
10.1.Overview
10.2. Key Findings
10.3. Market Segmentation
10.3.1. By Type
10.3.1.1.Early Onset Alzheimers
10.3.1.1.1.By Value (USD Million) 2022-2032F
10.3.1.1.2. Market Share (%) 2022-2032F
10.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
10.3.1.2. Late Onset Alzheimers
10.3.1.2.1. By Value (USD Million) 2022-2032F
10.3.1.2.2.Market Share (%) 2022-2032F
10.3.1.2.3.Y-o-Y Growth (%) 2022-2032F
10.3.1.3. Familial Alzheimers Disease
10.3.1.3.1. By Value (USD Million) 2022-2032F
10.3.1.3.2.Market Share (%) 2022-2032F
10.3.1.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.1.4. Others
10.3.1.4.1.By Value (USD Million) 2022-2032F
10.3.1.4.2. Market Share (%) 2022-2032F
10.3.1.4.3. Y-o-Y Growth (%) 2022-2032F
10.3.2.By Diagnostic Test
10.3.2.1. PET
10.3.2.1.1. By Value (USD Million) 2022-2032F
10.3.2.1.2.Market Share (%) 2022-2032F
10.3.2.1.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.2.SPECT
10.3.2.2.1.By Value (USD Million) 2022-2032F
10.3.2.2.2. Market Share (%) 2022-2032F
10.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
10.3.2.3.Blood based ELISA Test
10.3.2.3.1.By Value (USD Million) 2022-2032F
10.3.2.3.2. Market Share (%) 2022-2032F
10.3.2.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.4.CSF Assays
10.3.2.4.1. By Value (USD Million) 2022-2032F
10.3.2.4.2.Market Share (%) 2022-2032F
10.3.2.4.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.5.Others
10.3.2.5.1.By Value (USD Million) 2022-2032F
10.3.2.5.2.Market Share (%) 2022-2032F
10.3.2.5.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.By End User
10.3.3.1. Clinic
10.3.3.1.1. By Value (USD Million) 2022-2032F
10.3.3.1.2.Market Share (%) 2022-2032F
10.3.3.1.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.2.Hospital
10.3.3.2.1.By Value (USD Million) 2022-2032F
10.3.3.2.2. Market Share (%) 2022-2032F
10.3.3.2.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.3.Diagnostic Center
10.3.3.3.1.By Value (USD Million) 2022-2032F
10.3.3.3.2.Market Share (%) 2022-2032F
10.3.3.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.4.Others
10.3.3.4.1. By Value (USD Million) 2022-2032F
10.3.3.4.2.Market Share (%) 2022-2032F
10.3.3.4.3.Y-o-Y Growth (%) 2022-2032F
11.NORTH AMERICA ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1.By Type
11.3.2. By Diagnostic Test
11.3.3. By End User
11.4.Country
11.4.1. United States
11.4.2.Canada
12. EUROPE ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Type
12.3.2.By Diagnostic Test
12.3.3.By End User
12.4. Country
12.4.1.Germany
12.4.2. United Kingdom
12.4.3. France
12.4.4. Italy
12.4.5. Spain
12.4.6. Russia
12.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
13. ASIA ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Type
13.3.2.By Diagnostic Test
13.3.3.By End User
13.4. Country
13.4.1.India
13.4.2. China
13.4.3. South Korea
13.4.4. Japan
13.4.5. Rest of APAC
14. MIDDLE EAST AND AFRICA ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Type
14.3.2.By Diagnostic Test
14.3.3.By End User
14.4. Country
14.4.1.Israel
14.4.2. GCC
14.4.3. North Africa
14.4.4. South Africa
14.4.5. Rest of Middle East and Africa
15. LATIN AMERICA ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Type
15.3.2.By Diagnostic Test
15.3.3.By End User
15.4. Country
15.4.1.Mexico
15.4.2. Brazil
15.4.3. Rest of Latin America
16. COMPETITIVE LANDSCAPE
16.1. Company market share, 2021
16.2. Key player overview
16.3. Key stakeholders
17. COMPANY PROFILES
17.1.Johnson & Johnson
17.1.1.Company Overview
17.1.2. Financial Overview
17.1.3. Key Product; Analysis
17.1.4.Company Assessment
17.1.4.1.Product Portfolio
17.1.4.2. Key Clients
17.1.4.3. Market Share
17.1.4.4. Recent News & Development (Last 3 Yrs.)
17.1.4.5. Executive Team
17.2. Novartis AG
17.3. F. Hoffmann-La Roche Ltd
17.4. Pfizer Inc.
17.5. Merck & Co.
17.6. GE Healthcare
17.7. AbbVie
17.8. Eli Lilly and Company
17.9. Daiichi Sankyo
17.10. Sysmex
17.11.Quanterix
17.12. Alector LLC
17.13. Corium Inc
17.14. TauRx Therapeutics
17.15. Cognition Therapeutics Inc
17.16. Other Prominent Players
18. APPENDIX
19. CONSULTANT RECOMMENDATION
1.1.Regional Market Share
1.2. Business Trends
1.3. Alzheimers Disease Diagnostic Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot
2. RESEARCH METHODOLOGY
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6.Market Size Estimation and Data Triangulation
3. MARKET CHARACTERISTICS
3.1. Market Definition
3.2.Alzheimers Disease Diagnostic Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. ALZHEIMERS DISEASE DIAGNOSTIC MARKET – INDUSTRY INSIGHTS
4.1.Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5. MACROECONOMIC INDICATORS
6. RECENT DEVELOPMENTS
7.MARKET DYNAMICS
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends
8. MARKET ANALYSIS
8.1. Porters Five Forces
8.2. PEST Analysis
8.2.1. Political
8.2.2.Economic
8.2.3.Social
8.2.4.Technological
9. ALZHEIMERS DISEASE DIAGNOSTIC MARKET
9.1. Overview
9.2.Historical Analysis (2016-2021)
9.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
10. ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
10.1.Overview
10.2. Key Findings
10.3. Market Segmentation
10.3.1. By Type
10.3.1.1.Early Onset Alzheimers
10.3.1.1.1.By Value (USD Million) 2022-2032F
10.3.1.1.2. Market Share (%) 2022-2032F
10.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
10.3.1.2. Late Onset Alzheimers
10.3.1.2.1. By Value (USD Million) 2022-2032F
10.3.1.2.2.Market Share (%) 2022-2032F
10.3.1.2.3.Y-o-Y Growth (%) 2022-2032F
10.3.1.3. Familial Alzheimers Disease
10.3.1.3.1. By Value (USD Million) 2022-2032F
10.3.1.3.2.Market Share (%) 2022-2032F
10.3.1.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.1.4. Others
10.3.1.4.1.By Value (USD Million) 2022-2032F
10.3.1.4.2. Market Share (%) 2022-2032F
10.3.1.4.3. Y-o-Y Growth (%) 2022-2032F
10.3.2.By Diagnostic Test
10.3.2.1. PET
10.3.2.1.1. By Value (USD Million) 2022-2032F
10.3.2.1.2.Market Share (%) 2022-2032F
10.3.2.1.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.2.SPECT
10.3.2.2.1.By Value (USD Million) 2022-2032F
10.3.2.2.2. Market Share (%) 2022-2032F
10.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
10.3.2.3.Blood based ELISA Test
10.3.2.3.1.By Value (USD Million) 2022-2032F
10.3.2.3.2. Market Share (%) 2022-2032F
10.3.2.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.4.CSF Assays
10.3.2.4.1. By Value (USD Million) 2022-2032F
10.3.2.4.2.Market Share (%) 2022-2032F
10.3.2.4.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.5.Others
10.3.2.5.1.By Value (USD Million) 2022-2032F
10.3.2.5.2.Market Share (%) 2022-2032F
10.3.2.5.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.By End User
10.3.3.1. Clinic
10.3.3.1.1. By Value (USD Million) 2022-2032F
10.3.3.1.2.Market Share (%) 2022-2032F
10.3.3.1.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.2.Hospital
10.3.3.2.1.By Value (USD Million) 2022-2032F
10.3.3.2.2. Market Share (%) 2022-2032F
10.3.3.2.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.3.Diagnostic Center
10.3.3.3.1.By Value (USD Million) 2022-2032F
10.3.3.3.2.Market Share (%) 2022-2032F
10.3.3.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.4.Others
10.3.3.4.1. By Value (USD Million) 2022-2032F
10.3.3.4.2.Market Share (%) 2022-2032F
10.3.3.4.3.Y-o-Y Growth (%) 2022-2032F
11.NORTH AMERICA ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1.By Type
11.3.2. By Diagnostic Test
11.3.3. By End User
11.4.Country
11.4.1. United States
11.4.2.Canada
12. EUROPE ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Type
12.3.2.By Diagnostic Test
12.3.3.By End User
12.4. Country
12.4.1.Germany
12.4.2. United Kingdom
12.4.3. France
12.4.4. Italy
12.4.5. Spain
12.4.6. Russia
12.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
13. ASIA ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Type
13.3.2.By Diagnostic Test
13.3.3.By End User
13.4. Country
13.4.1.India
13.4.2. China
13.4.3. South Korea
13.4.4. Japan
13.4.5. Rest of APAC
14. MIDDLE EAST AND AFRICA ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Type
14.3.2.By Diagnostic Test
14.3.3.By End User
14.4. Country
14.4.1.Israel
14.4.2. GCC
14.4.3. North Africa
14.4.4. South Africa
14.4.5. Rest of Middle East and Africa
15. LATIN AMERICA ALZHEIMERS DISEASE DIAGNOSTIC MARKET SIZE & FORECAST 2022A-2032F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Type
15.3.2.By Diagnostic Test
15.3.3.By End User
15.4. Country
15.4.1.Mexico
15.4.2. Brazil
15.4.3. Rest of Latin America
16. COMPETITIVE LANDSCAPE
16.1. Company market share, 2021
16.2. Key player overview
16.3. Key stakeholders
17. COMPANY PROFILES
17.1.Johnson & Johnson
17.1.1.Company Overview
17.1.2. Financial Overview
17.1.3. Key Product; Analysis
17.1.4.Company Assessment
17.1.4.1.Product Portfolio
17.1.4.2. Key Clients
17.1.4.3. Market Share
17.1.4.4. Recent News & Development (Last 3 Yrs.)
17.1.4.5. Executive Team
17.2. Novartis AG
17.3. F. Hoffmann-La Roche Ltd
17.4. Pfizer Inc.
17.5. Merck & Co.
17.6. GE Healthcare
17.7. AbbVie
17.8. Eli Lilly and Company
17.9. Daiichi Sankyo
17.10. Sysmex
17.11.Quanterix
17.12. Alector LLC
17.13. Corium Inc
17.14. TauRx Therapeutics
17.15. Cognition Therapeutics Inc
17.16. Other Prominent Players
18. APPENDIX
19. CONSULTANT RECOMMENDATION
